期刊文献+

N-乙酰氨基半乳糖转移酶7在乳腺癌中的表达及临床意义

The expression and clinical significance of GALNT7 in breast cancer
原文传递
导出
摘要 目的检测N-乙酰氨基半乳糖转移酶7(GALNT7)在乳腺癌与正常组织和细胞中的表达,并分析其表达水平与临床病理特征间的关系。方法采用实时定量反转录-聚合酶链反应(RT-QPCR)法检测GALNT7在40对乳腺癌组织和癌旁正常组织中的表达,运用Mann-Whitney法分析乳腺癌组织中GALNT7表达与患者临床病理特征之间的相关性。培养乳腺癌细胞株(MCF-7和MDA—MB-231)和正常乳腺上皮细胞株(MCF-10A)并采用实时荧光定量PCR方法检测GALNT7表达量。结果GALNT7在乳腺癌组织中的相对表达量为1.09917±0.01756,癌旁正常组织为0.65218±0.07652,两组比较差异有统计学意义(P〈0.01),且乳腺癌组织中GALNT7表达量与患者ER受体表达呈负相关(P=0.016),与其他临床病理资料如年龄、肿瘤大小、PR和HER-2受体表达、临床分期及淋巴结转移无相关关系(P〉0.05)。GALNT7在乳腺癌细胞系中的表达量高于正常乳腺上皮细胞系(P〈0.001),且ER阴性乳腺癌细胞系MDA—MB-231的GALNT7表达量是ER阳性乳腺癌细胞系MCF-7的2.06倍(P〈0.05)。结论GALNT7在乳腺癌组织和细胞株中均高表达,其在乳腺癌组织和细胞系中的表达与ER受体的表达密切相关,GALNT7与乳腺癌的发生发展相关。 Objective In the present study,the GALNT7 expression level was detected in paired breast cancer tissues and cell lines, and the relationship between GALNT7 expression and clinicopathology was analyzed. This study laid a foundation for further functional and mechanic study. Method RT-qPCR was performed to detect the expression of GALNT7 in 40 paired breast cancer tissues and adjacent tissues. The statistical analysis, Mann-Whitney U test,was used to verify the relationship between GALNT7 expression and clinicopathological features. RT-qPCR also performed to confirm the GALNT7 expressions in breast cancer cell lines (MCF-7 and MDA-MB-231 )and normal breast epithelial cell line (MCF-10A). Results The expression level of GALNT7 is significantly higher in breast cancer tissues ( P 〈 0. 001 ) and cell lines( P 〈 0. 001 ) compared with normal breast tissues and normal epithelial cell line. And the GALNT7 expression in breast cancer tissues is negatively correlated with the expression of ER ,but no obvious correlation was found between GALNT7 expression and other clinicopathological variables, such as age, tumor size, PR, Her-2 expression, clinical stages and lymph nodes metastasis ( P 〉 0.05 ). Conclusion GALNT7 was overexpressed in breast cancer tissues and cell lines, and correlated negatively with ER expression in breast cancer tissues,which suggested that GALNT7 might be involved in breast cancer occurrence and development.
出处 《临床外科杂志》 2015年第12期909-912,共4页 Journal of Clinical Surgery
基金 2014年北京大学深圳医院科研基金资助项目(201438)
关键词 N-乙酰氨基半乳糖转移酶7 乳腺癌 雌激素受体 N-Acetylgalactosaminyltransferase 9 breast cancer estrogen receptor
  • 相关文献

参考文献7

  • 1Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014 [ J ]. CA Cancer J Clin,2014,64( 1 ) :9-29.
  • 2Cao W, Wang X, Li JC. Hereditary breast cancer in the Han Chinese population [ J ]. J Epidemio1,2013,23 (2) :75-84.
  • 3Rfittger S, White J, Wandall HH, et al. Localization of three human polypeptide GalNAc-transferases in HeLa cells suggests initiation of O- linked glycosylation throughout the Golgi apparatus [ J ]. J Cell Sci, 1998,111(Pt 1 ) :45-60.
  • 4Gaziel-Sovran A, Segura MF, Di Micco R, et al. miR-30b/30d regula- tion of GalNAc transferases enhances invasion and immunosuppression during metastasis[ J]. Cancer Cell ,2011,20( 1 ) : 104-118.
  • 5Peng RQ,Wan HY, Li HF, et al. MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-alpha-D-galactosamine : polypeptide N erase 7 [ J ]. J Biol Chem,2012,287 ( 17 ) : 14301-14309.
  • 6Li W, Ma H, Sun J. MieroRNA34a/e function as tumor suppressors in Hep2 laryngeal carcinoma cells and may reduce GALNT7 expression [ J]. Mol Med Rep,2014,9(4) : 1293-1298.
  • 7沈娜,宋海平,赵月,郭辉,赵向旺,姜冉,何文山,黄韬.乳腺癌雌激素受体阳性细胞对雌激素受体阴性细胞增殖的影响[J].华中科技大学学报(医学版),2012,41(1):45-48. 被引量:7

二级参考文献14

  • 1Martinez-Prieto M,Flores D L T C,Rivera R S,et al.Horm-onal therapy in metastatic breast cancer[J].Ginecol Obstet Mex,2009,77(10):482-486.
  • 2Allred D C,Carlson R W,Berry D A,et al.NCCN task force report:Estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry[J].J Natl Compr Canc Netw,2009,7(Suppl 6):S1-S21,S22-S23.
  • 3Musgrove E A,Sutherland R L.Biological determinants of endocrine resistance in breast cancer[J].Nat Rev Cancer,2009,9(9):631-643.
  • 4Collins L C,Botero M L,Schnitt S J.Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer:an analysis of 825 cases[J].Am J Clin Pathol,2005,123(1):16-20.
  • 5Cleator S J,Ahamed E,Coombes R C,et al.A 2009 update on the treatment of patients with hormone receptor-positive breast cancer[J].Clin Breast Cancer,2009,9(Suppl 1):S6-S17.
  • 6Harvey J M,Clark G M,Osborne C K,et al.Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer[J].J Clin Oncol,1999,17(5):1474-1481.
  • 7Hammond M E,Hayes D F,Dowsett M,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer(unabridged version)[J].Arch Pathol Lab Med,2010,134(7):e48-e72.
  • 8Dixon J M,Love C D,Bellamy C O,et al.Letrozole as primary medical therapy for locally advanced and large operable breast cancer[J].Breast Cancer Res Treat,2001,66(3):191-199.
  • 9Dombernowsky P,Smith I,Falkson G,et al.Letrozole,a new oral aromatase inhibitor for advanced breast cancer:double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate[J].J Clin Oncol,1998,16(2):453-461.
  • 10Buzdar A,Jonat W,Howell A,et al.Anastrozole,a potent and selective aromatase inhibitor,versus megestrol acetate in postmenopausal women with advanced breast cancer:results of overview analysis of two phase Ⅲ trials.Arimidex Study Group[J].J Clin Oncol,1996,14(7):2000-2011.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部